The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
Open accessAbstract
In type-2 diabetes, the overall incretin effect is reduced. The present investigation was designed to compare insulinotropic actions of exogenous incretin hormones (gastric inhibitory peptide [GIP] and glucagon-like peptide 1 [GLP-1] [7-36 amide]) in nine type-2 diabetic patients (fasting plasma glucose 7.8 mmol/liter; hemoglobin A1c 6.3 +/- 0.6%) and in nine age- and weight-matched normal subjects. Synthetic human GIP (0.8 and 2.4 pmol/kg.min over 1 h each), GLP-1 [7-36 amide] (0.4 and 1.2 pmol/kg.min over 1 h each), and placebo were administered under hyperglycemic clamp conditions (8.75 mmol/liter) in separate experiments. Plasma GIP and GLP-1 [7-36 amide] concentrations (radioimmunoassay) were comparable to those after oral glucose with the low, and clearly supraphysiological with the high infusion rates. Both GIP and GLP-1 [7-36 amide] dose-dependently augmented insulin secretion (insulin, C-peptide) in both groups (P < 0.05). With GIP, the maximum effect in type-2 diabetic patients was significantly lower (by 54%; P < 0.05) than in normal subjects. With GLP-1 [7-36 amide] type-2 diabetic patients reached 71% of the increments in C-peptide of normal subjects (difference not significant). Glucagon was lowered during hyperglycemic clamps in normal subjects, but not in type-2 diabetic patients, and further by GLP-1 [7-36 amide] in both groups (P < 0.05), but not by GIP. In conclusion, in mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity. It also lowers glucagon concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2DM, there is a decrease in the incretin effect which primarily attributed to the diminished effects of gastric inhibitory polypeptide (GIP).9”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite the slight differences based on the subject cohort and the duration of treatment, this magnitude of weight loss was largely consistent with the SURPASS trials132-140.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredIn the citing paper
“which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absent incretin effect of GIP in T2D [22,23].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [23]
In the citing paper
“However, GIP action is lost in T2D and even infusions of GIP that result in supraphysiological concentrations fail to elicit a significant insulin secretory response in T2D patients.160”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [160]
In the citing paper
“in type 2 diabetes, a markedly attenuated insulinotropic action of GIP (66) and, in some cases, attenuated secretion of GLP-1 (67), contribute to an impairment of postprandial insulin secretion, so that the latter is insufficient to maintain euglycaemia.”
From Gut mechanisms linking intestinal sweet sensing to glycemic control (2018) · cites this paper as [66]
In the citing paper
“In the setting of GIP/GLP-1 receptor agonist (dual agonism), GLP-1 quells the potential glucagon-stimulatory effects of GIP (64) and also (re)sensitizes beta cells to GIP's incretin effects (57), all while potentially enhancing GIP's beneficial effects on weight regulation mechanisms.”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“It remained in the shadow of GLP-1, partly because GIP-stimulated insulin secretion is significantly blunted in individuals with T2D (56); notably, responsiveness can be restored by mitigating hyperglycemia (57).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [57]
In the citing paper
“GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 889
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [45]45. Creutzfeldt, W., and U. R. Folsch. 1983. Delaying Absorption as a Thera- peutic Principle in Metabolic Disease. Georg-Thieme-Verlag, Stuttgart.
Cited by
Sorted by citations
Items 401–500 of 1,003
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
Meirelles, K., Ahmed, T., Culnan, D. M., Lynch, C. J., Lang, C. H., & Cooney, R. N. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181904af0 · Cited by 86
Hansen, L., Hartmann, B., Mineo, H., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.021 · Cited by 79
Self-citationLyseng-Williamson, K. A. (2007) · Drugs · doi:10.2165/00003495-200767040-00007 · Cited by 81
Varney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 84
Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 84
Targeting postprandial hyperglycemia
Rendell, M., & Jovanovič, L. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.012 · Cited by 80
What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 86
Self-citationSeino, Y., Fujita, T., Hiroi, S., Hirayama, M., & Kaku, K. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.599371 · Cited by 79
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Ceriello, A., Novials, A., Canivell, S., Sala, L. L., Pujadas, G., Esposito, K., Testa, R., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2014) · Diabetes Care · doi:10.2337/dc13-2618 · Cited by 78
The Incretin Notion and its Relevance to Diabetes
Habener, J. F. (1993) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30135-x · Cited by 78
Meier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 77
Self-citationZhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 78
Dysglycaemia in the critically ill – significance and management
Deane, A. M., & Horowitz, M. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12078 · Cited by 78
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 76
Self-citationIncretins and other peptides in the treatment of diabetes
Todd, J. F., & Bloom, S. R. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.02071.x · Cited by 76
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
Kubota, Y., Miyamoto, M., Takagi, G., Ikeda, T., Kirinoki‐Ichikawa, S., Tanaka, K., & Mizuno, K. (2012) · Journal of Korean Medical Science · doi:10.3346/jkms.2012.27.11.1364 · Cited by 76
Vilsbøll, T., Agersø, H., Lauritsen, T. L. B., Deacon, C. F., Aaboe, K., Madsbad, S., Krarup, T., & Holst, J. J. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.07.007 · Cited by 75
Self-citationThe Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties
Irwin, D. M., Satkunarajah, M., Wen, Y., Brubaker, P. L., Pederson, R. A., & Wheeler, M. B. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.7915 · Cited by 73
Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function
Koole, C., Pabreja, K., Savage, E. E., Wootten, D. L., Furness, S. G. B., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120236 · Cited by 77
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 76
Fritsche, A., Stefan, N., Hardt, E., Häring, H., & Stümvoll, M. (2000) · Diabetologia · doi:10.1007/s001250051461 · Cited by 76
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Jean, M., Alameh, M., Jesus, D. D., Thibault, M., Lavertu, M., Darras, V., Nelea, M. I., Buschmann, M. D., & Merzouki, A. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.029 · Cited by 81
Advances in therapy for type 2 diabetes: GLP–1 receptor agonists and DPP–4 inhibitors
Kennedy, L., & Davidson, J. A. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.05 · Cited by 75
Schmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74
He, Y., Sadler, B. M., Sabo, R., Balez, S., Wang, Y., Campestrini, J., Laurent, A. L., Ligueros‐Saylan, M., & Howard, D. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746090-00006 · Cited by 75
Wice, B. M., Wang, S., Crimmins, D. L., Diggs‐Andrews, K. A., Althage, M. C., Ford, E. L., Tran, H. D., Ohlendorf, M. F., Griest, T. A., Wang, Q., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.129304 · Cited by 74
Wice, B. M., Reeds, D. N., Tran, H. D., Crimmins, D. L., Patterson, B. W., Dunai, J., Wallendorf, M., Ladenson, J. H., Villareal, D. T., & Polonsky, K. S. (2012) · Diabetes · doi:10.2337/db11-1451 · Cited by 75
Holst, J. J., & Ørskov, C. (2001) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/clb.61.234.75.85 · Cited by 77
Self-citationWoerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
Timper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N. S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.003 · Cited by 67
The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum
Hansen, L., & Holst, J. J. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00157-x · Cited by 73
Self-citationMoritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.018 · Cited by 73
Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
Lee, S., Yabe, D., Nohtomi, K., Takada, M., Morita, R., Seino, Y., & Hirano, T. (2010) · Endocrine Journal · doi:10.1507/endocrj.k09e-269 · Cited by 74
Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets
Zhou, J., Livak, M. F. A., Bernier, M., Muller, D. C., Carlson, O. D., Elahi, D., Maudsley, S. R., & Egan, J. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00070.2007 · Cited by 76
Narita, T., Yokoyama, H., Yamashita, R., Sato, T. K., Hosoba, M., Morii, T., Fujita, H., Tsukiyama, K., & Yamada, Y. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01526.x · Cited by 72
Frías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 75
Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery
Svane, M. S., Bojsen-Møller, K. N., Nielsen, S. T., Jørgensen, N. B., Dirksen, C., Bendtsen, F., Kristiansen, V. B., Hartmann, B., Holst, J. J., & Madsbad, S. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00471.2015 · Cited by 69
Self-citationDamholt, A. B., Buchan, A. M. J., & Kofod, H. (1998) · Endocrinology · doi:10.1210/endo.139.4.5921 · Cited by 72
Mathi, S. K., Chan, Y., Li, X., & Wheeler, M. B. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.4.9913 · Cited by 71
Terasaki, M., Nagashima, M., Nohtomi, K., Kohashi, K., Tomoyasu, M., Shinmura, K., Nogi, Y., Katayama, Y., Sato, K., Itoh, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070933 · Cited by 71
The incretins: a link between nutrients and well-being
Burcelin, R. (2005) · British Journal Of Nutrition · doi:10.1079/bjn20041340 · Cited by 71
Chaikomin, R., Doran, S., Jones, K. L., Feinle‐Bisset, C., O’Donovan, D., Rayner, C. K., & Horowitz, M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00099.2005 · Cited by 71
Renner, S., Dobenecker, B., Blutke, A., Zöls, S., Wanke, R., Ritzmann, M., & Wolf, E. (2016) · Theriogenology · doi:10.1016/j.theriogenology.2016.04.055 · Cited by 75
O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., & Flatt, P. R. (2002) · Diabetologia · doi:10.1007/s00125-002-0894-6 · Cited by 72
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
Self-citationRole of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Pathak, V., Flatt, P. R., & Irwin, N. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.007 · Cited by 70
Rajput, D. S., Basha, S. M., Xin, Q., Gadekallu, T. R., Kaluri, R., Lakshmanna, K., & Maddikunta, P. K. R. (2021) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-021-03154-4 · Cited by 75
de Heer, J., Pedersen, J., Ørskov, C., & Holst, J. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0761-6 · Cited by 69
Self-citationHu, G., Jousilahti, P., Peltonen, M., Bidel, S., & Tuomilehto, J. O. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803341 · Cited by 68
Signalling in the gut endocrine axis
Gribble, F. M., & Reimann, F. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.039 · Cited by 66
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 77
GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women
Rudovich, N. N., Kaiser, S., Engeli, S., Osterhoff, M. A., Gögebakan, Ö., Blüher, M., & Pfeiffer, A. F. H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2007.02.006 · Cited by 68
Almind, K., Ambye, L., Urhammer, S. A., Hansen, T. F., Echwald, S. M., Holst, J. J., Gromada, J., Thorens, B., & Pedersen, O. B. (1998) · Diabetologia · doi:10.1007/s001250051051 · Cited by 68
Self-citationLim, S. K., Kim, K. M., & Nauck, M. A. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.01.011 · Cited by 70
Self-citationGut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
“The early studies by Nauck and Holst have shown that the actions of GLP-1 and GIP on insulin secretion are nearly equal and additive in healthy humans [20,21], which is not observed in the set of T2D where the endocrine pancreas ceases responsiveness to GIP but remains responsive to GLP-1, explaining the reduced/absen…”
BackgroundPreservation of β-cell function by targeting β-cell mass
DEKONING, E., Bonner‐Weir, S., & Rabelink, T. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.001 · Cited by 69
Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes Mellitus
Langley, A., Suffoletta, T. J., & Jennings, H. R. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.8.1163 · Cited by 65
Mudaliar, S. R. D., & Henry, R. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.006 · Cited by 68
Bench-to-bedside review: The gut as an endocrine organ in the critically ill
Deane, A. M., Chapman, M. J., Fraser, R. J., & Horowitz, M. (2010) · Critical Care · doi:10.1186/cc9039 · Cited by 65
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
Lovshin, J. A. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.08.242 · Cited by 67
Alogliptin: a new addition to the class of DPP-4 inhibitors
Rendell, M. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s4312 · Cited by 66
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 67
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 66
Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Daousi, C., Wilding, J. P. H., Aditya, S., Durham, B. H., Cleator, J., Pinkney, J. H., & Ranganath, L. R. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03451.x · Cited by 64
Zhang, M., Robitaille, M., Showalter, A. D., Huang, X., Liu, Y., Bhattacharjee, A., Willard, F. S., Han, J., Froese, D. S., Li, W., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.040196 · Cited by 68
Fate of the beta-cell in the pathophysiology of type 2 diabetes
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09076 · Cited by 64
Schirra, J. R. J., Leicht, P., Hildebrand, P., Beglinger, C., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1560177 · Cited by 65
The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
Hayes, M. R., Borner, T., & Jonghe, B. C. D. (2021) · Diabetes · doi:10.2337/dbi21-0004 · Cited by 65
Whitaker, G. M., Lynn, F. C., McIntosh, C. H. S., & Accili, E. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032675 · Cited by 66
Role of Pancreatic Transcription Factors in Maintenance of Mature β-Cell Function
Kaneto, H., & Matsuoka, T. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036281 · Cited by 67
Reimann, F. M., & Gribble, F. M. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12478 · Cited by 64
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 68
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
The future of incretin‐based therapy: novel avenues—novel targets
Åhrén, B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01457.x · Cited by 62
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
Gallwitz, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
Kennedy, L., & Freeman, J. S. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76.s5.03 · Cited by 63
Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
Hu, P., Yin, Q., Deckert, F., Jiang, J., Liu, D., Kjems, L., Dole, W. P., & He, Y. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008325152 · Cited by 63
DPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., & Campbell, R. K. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m134 · Cited by 63
Characterization of glucagon-like peptide-1 receptor-binding determinants
Xiao, Q. F., Jeng, W., & Wheeler, M. B. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250321 · Cited by 63
Albrechtsen, N. J. W., Kuhre, R. E., Toräng, S., & Holst, J. J. (2016) · BMC Research Notes · doi:10.1186/s13104-016-1872-2 · Cited by 63
Self-citationGlucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease
Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 63
Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62
Self-citationA Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63
Mikhail, N. E. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.845 · Cited by 63
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 62
Self-citationMøller, C. L., Vistisen, D., Færch, K., Johansen, N. B., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Jørgensen, M. E., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3133 · Cited by 64
Self-citationBastin, M., & Andréelli, F. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s191438 · Cited by 63
Ritzel, R. A., Schulte, M., Pørksen, N. K., Nauck, M., Holst, J. J., Juhl, C. B., März, W., Schmitz, O., Schmiegel, W., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.4.776 · Cited by 62
Self-citationThe Role of cAMP in Beta Cell Stimulus–Secretion and Intercellular Coupling
Stožer, A., Leitgeb, E. P., Pohorec, V., Dolenšek, J., Bombek, L. K., Gosak, M., & Klemen, M. S. (2021) · Cells · doi:10.3390/cells10071658 · Cited by 72
Molecular mechanisms underlying nutrient detection by incretin-secreting cells
Reimann, F. M. (2009) · International Dairy Journal · doi:10.1016/j.idairyj.2009.11.014 · Cited by 58
de Carvalho, C. P., Marin, D. M., de Souza, A. L., Pareja, J. C., Chaim, É. A., de Barros-Mazon, S., da Silva, C. A., Geloneze, B., Muscelli, E., & Alegre, S. M. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9678-5 · Cited by 61
Vardarli, I., Nauck, M. A., Köthe, L., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2178 · Cited by 62
Self-citationVella, A. V., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Ligueros‐Saylan, M., Deacon, C. F., Foley, J. E., Rizza, R. A., & Camilleri, M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03235.x · Cited by 62
Metadata
- Authors
- Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W.
- Affiliations
- University of Göttingen (DE)
- University of Copenhagen (DK)
- Rigshospitalet (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1993-01-01
- Volume
- 91
- Issue
- 1
- Pages
- 301-307
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC330027
- OpenAlex
- W1969932276
- Cited by
- 1,651
- References
- 41
- Citations by year
- 2026: 45 · 2025: 51 · 2024: 63 · 2023: 63 · 2022: 57 · 2021: 57 · 2020: 50 · 2019: 70 · 2018: 50 · 2017: 49 · 2016: 71 · 2015: 62 · 2014: 75 · 2013: 84 · 2012: 59
- FWCI
- 16.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (203/2-1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, glucose-dependent insulinotropic polypeptide, type 2 diabetes, insulin secretion, C-peptide, glucagon, hyperglycemic clamp, incretin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glucagon, Glycated Hemoglobin, Humans, Insulin, Kinetics, Male, Middle Aged, Peptide Fragments, Protein Precursors, Reference Values, Time Factors, Glucose Clamp Technique, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
